GPT and metabolic dysfunction-associated steatotic liver disease: Both Salvazo et al. [22] and Cermelli et al. [25] showed better, or at least similar, curve characteristics (Table 3) than for ALT, suggesting that serum miR122 levels can be used as a biomarker to discriminate NAFLD patients from healthy controls.